论文部分内容阅读
目的:比较~(131)I与抗甲亢药物(ATD)治疗甲亢的疗效。方法:选择首诊的甲亢患者200例,随机分为两组:~(131)I治疗组与ATD对照组各100例。观察~(131)I与ATD治疗后突眼、甲减及甲亢复发的情况,并观察~(131)I与ATD治疗甲亢并发症的疗效及不良反应。结果:~(131)I与ATD组发生甲减的差异无统计学意义。两组突眼的转归也无差异。~(131)I治疗复发率明显低于ATD组。~(131)I治疗甲亢心脏病疗效优于ATD。~(131)I治疗出现肝损伤、白细胞减少等不良反应低于ATD。结论:~(131)I治疗甲亢是安全有效的,其综合疗效优于抗甲亢药物。
Objective: To compare the curative effect of ~ (131) I and anti hyperthyroidism (ATD) in the treatment of hyperthyroidism. Methods: A total of 200 hyperthyroid patients were selected and randomly divided into two groups: 100 in 131I-treated group and ATD-control group. To observe the recurrence of exophthalmos, hypothyroidism and hyperthyroidism after ~ (131) I and ATD treatment, and observe the curative effect and adverse reactions of ~ (131) I and ATD in the treatment of complications of hyperthyroidism. Results: There was no significant difference in hypothyroidism between ~ (131) I and ATD group. There was no difference in the outcome of two groups of exophthalmos. The recurrence rate of ~ (131) I treatment was significantly lower than that of ATD group. ~ (131) I treatment of hyperthyroidism heart disease better than ATD. ~ (131) I treatment of liver damage, leukopenia and other adverse reactions than ATD. Conclusion: 131I treatment of hyperthyroidism is safe and effective, and its comprehensive curative effect is superior to that of antihyperhyhcosis.